12.6 Clickable Radionanomedicine Platform
Radionanomedicine platform can be devised by combining amphiphile encapsulation method and click chemistry. Hydrophilic monodispersed nanomaterials can
be prepared by using an amphiphile encapsulation method. And terminal click
moiety on the nanomaterial surface can be used for conjugation of targeting
molecules, radioisotopes, optical probes, and/or therapeutic drugs by click chemistry (Fig. 12.4). For this radionanomedicine platform, the FDA approval process
can be done for each separate vials, such as nano platform, targeting molecule,
radioisotope-chelator, optical probe, and therapeutic drug, independently. And the
final use of radionanomedicine platform by the simple compounding process at the
clinical practice sites.
Here we propose the final goal of the versatile radionanomedicine platform that
looks to multi-purpose uses for diagnosis, therapy, or even theragnosis by using one
nano-platform in the clinic. For example, a patient can be diagnosed specifically by
the image or in vitro assay using the adequate diagnostic nano-platform containing
proper targeting molecule and radioisotope combination. Thus, we can select proper
therapeutic drug or radionuclide for therapy of this disease (Fig. 12.5).
In conclusion, the multi-purpose versatile radionanomedicine platform, can be
established by the combination of amphiphile encapsulation and the click chemistry, show another possibility of radionanomedicine and would contribute the
successful translation journey to the clinical application of nanomedicine.
Fig. 12.5 Possible clinical application of radionanomedicine using nano-platform
246
Y.-S. Lee et al.
Radionanomedicine platform can be devised by combining amphiphile encapsulation method and click chemistry. Hydrophilic monodispersed nanomaterials can
be prepared by using an amphiphile encapsulation method. And terminal click
moiety on the nanomaterial surface can be used for conjugation of targeting
molecules, radioisotopes, optical probes, and/or therapeutic drugs by click chemistry (Fig. 12.4). For this radionanomedicine platform, the FDA approval process
can be done for each separate vials, such as nano platform, targeting molecule,
radioisotope-chelator, optical probe, and therapeutic drug, independently. And the
final use of radionanomedicine platform by the simple compounding process at the
clinical practice sites.
Here we propose the final goal of the versatile radionanomedicine platform that
looks to multi-purpose uses for diagnosis, therapy, or even theragnosis by using one
nano-platform in the clinic. For example, a patient can be diagnosed specifically by
the image or in vitro assay using the adequate diagnostic nano-platform containing
proper targeting molecule and radioisotope combination. Thus, we can select proper
therapeutic drug or radionuclide for therapy of this disease (Fig. 12.5).
In conclusion, the multi-purpose versatile radionanomedicine platform, can be
established by the combination of amphiphile encapsulation and the click chemistry, show another possibility of radionanomedicine and would contribute the
successful translation journey to the clinical application of nanomedicine.
Fig. 12.5 Possible clinical application of radionanomedicine using nano-platform
246
Y.-S. Lee et al.